Top

Published in:

01-03-2021 | Ovarian Cancer | Clinical

The role of caspase-8 in the tumor microenvironment of ovarian cancer

Authors: Izabela Kostova, Ranadip Mandal, Sven Becker, Klaus Strebhardt

Published in: Cancer and Metastasis Reviews | Issue 1/2021

Abstract

Caspase-8 is an aspartate-specific cysteine protease, which is best known for its apoptotic functions. Caspase-8 is placed at central nodes of multiple signal pathways, regulating not only the cell cycle but also the invasive and metastatic cell behavior, the immune cell homeostasis and cytokine production, which are the two major components of the tumor microenvironment (TME). Ovarian cancer often has dysregulated caspase-8 expression, leading to imbalance between its apoptotic and non-apoptotic functions within the tumor and the surrounding milieu. The downregulation of caspase-8 in ovarian cancer seems to be linked to high aggressiveness with chronic inflammation, immunoediting, and immune resistance. Caspase-8 plays therefore an essential role not only in the primary tumor cells but also in the TME by regulating the immune response, B and T lymphocyte activation, and macrophage differentiation and polarization. The switch between M1 and M2 macrophages is possibly associated with changes in the caspase-8 expression. In this review, we are discussing the non-apoptotic functions of caspase-8, highlighting this protein as a modulator of the immune response and the cytokine composition in the TME. Considering the low survival rate among ovarian cancer patients, it is urgently necessary to develop new therapeutic strategies to optimize the response to the standard treatment. The TME is highly heterogenous and provides a variety of opportunities for new drug targets. Given the variety of roles of caspase-8 in the TME, we should focus on this protein in the development of new therapeutic strategies against the TME of ovarian cancer.

Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA Cancer J Clin, 70(1), 7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Ghoneum, A., Afify, H., Salih, Z., Kelly, M., & Said, N. (2018). Role of tumor microenvironment in the pathobiology of ovarian cancer: insights and therapeutic opportunities. Cancer Medicine, 7(10), 5047–5056. https://doi.org/10.1002/cam4.1741.CrossRefPubMedPubMedCentral

Brasseur, K., Gevry, N., & Asselin, E. (2017). Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget, 8(3), 4008–4042. https://doi.org/10.18632/oncotarget.14021.CrossRefPubMed

Kossai, M., Leary, A., Scoazec, J. Y., & Genestie, C. (2018). Ovarian cancer: a heterogeneous disease. Pathobiology, 85(1-2), 41–49. https://doi.org/10.1159/000479006.CrossRefPubMed

Chandra, A., Pius, C., Nabeel, M., Nair, M., Vishwanatha, J. K., Ahmad, S., et al. (2019). Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med, 8(16), 7018–7031. https://doi.org/10.1002/cam4.2560.CrossRefPubMedPubMedCentral

Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., et al. (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res, 14(16), 5198–5208. https://doi.org/10.1158/1078-0432.CCR-08-0196.CrossRefPubMed

Hernandez, L., Kim, M. K., Noonan, A. M., Sagher, E., Kohlhammer, H., Wright, G., et al. (2015). A dual role for caspase8 and NF-kappaB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival. Cell Death Discov, 1, 15053. https://doi.org/10.1038/cddiscovery.2015.53.CrossRefPubMedPubMedCentral

Hansen, J. M., Coleman, R. L., & Sood, A. K. (2016). Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer, 56, 131–143. https://doi.org/10.1016/j.ejca.2015.12.016.CrossRefPubMedPubMedCentral

Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N. F. F., Pluddemann, A., et al. (2006). Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. Journal of Immunology, 176(8), 5023–5032. https://doi.org/10.4049/jimmunol.176.8.5023.CrossRef

10.

Maelfait, J., & Beyaert, R. (2008). Non-apoptotic functions of caspase-8. Biochemical Pharmacology, 76(11), 1365–1373. https://doi.org/10.1016/j.bcp.2008.07.034.CrossRefPubMed

11.

Aghababazadeh, M., Dorraki, N., Javan, F. A., Fattahi, A. S., Gharib, M., & Pasdar, A. (2017). Downregulation of caspase 8 in a group of Iranian breast cancer patients - a pilot study. J Egypt Natl Canc Inst, 29(4), 191–195. https://doi.org/10.1016/j.jnci.2017.10.001.CrossRefPubMed

12.

McIlwain, D. R., Berger, T., & Mak, T. W. (2013). Caspase functions in cell death and disease. Cold Spring Harbor Perspectives in Biology, 5(4), ARTN a008656. https://doi.org/10.1101/cshperspect.a008656.CrossRef

13.

Kumar, S. (2007). Caspase function in programmed cell death. Cell Death and Differentiation, 14(1), 32–43. https://doi.org/10.1038/sj.cdd.4402060.CrossRefPubMed

14.

Mandal, R., Barron, J. C., Kostova, I., Becker, S., & Strebhardt, K. (2020). Caspase-8: The double-edged sword. Biochim Biophys Acta Rev Cancer, 188357. https://doi.org/10.1016/j.bbcan.2020.188357.

15.

Tummers, B., & Green, D. R. (2017). Caspase-8: regulating life and death. Immunol Rev, 277(1), 76–89. https://doi.org/10.1111/imr.12541.CrossRefPubMedPubMedCentral

16.

Ichim, G., & Tait, S. W. (2016). A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer, 16(8), 539–548. https://doi.org/10.1038/nrc.2016.58.CrossRefPubMed

17.

Matthess, Y., Raab, M., Sanhaji, M., Lavrik, I. N., & Strebhardt, K. (2010). Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. [Research Support, Non-U.S. Gov't]. Mol Cell Biol, 30(24), 5726–5740. https://doi.org/10.1128/MCB.00731-10.CrossRefPubMedPubMedCentral

18.

Muzio, M., Stockwell, B. R., Stennicke, H. R., Salvesen, G. S., & Dixit, V. M. (1998). An induced proximity model for caspase-8 activation. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. J Biol Chem, 273(5), 2926–2930.CrossRefPubMed

19.

Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Cell, 94(4), 481–490.CrossRefPubMed

20.

Yadav, V. K., Lakshmi, G., & Medhamurthy, R. (2005). Prostaglandin F2alpha-mediated activation of apoptotic signaling cascades in the corpus luteum during apoptosis: involvement of caspase-activated DNase. J Biol Chem, 280(11), 10357–10367. https://doi.org/10.1074/jbc.M409596200.CrossRefPubMed

21.

Bejarano, I., Rodriguez, A. B., & Pariente, J. A. (2018). Apoptosis is a demanding selective tool during the development of fetal male germ cells. Front Cell Dev Biol, 6, 65. https://doi.org/10.3389/fcell.2018.00065.CrossRefPubMedPubMedCentral

22.

Soung, Y. H., Lee, J. W., Kim, S. Y., Jang, J., Park, Y. G., Park, W. S., et al. (2005). CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res, 65(3), 815–821.PubMed

23.

Soung, Y. H., Lee, J. W., Kim, S. Y., Sung, Y. J., Park, W. S., Nam, S. W., et al. (2005). Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. Oncogene, 24(1), 141–147. https://doi.org/10.1038/sj.onc.1208244.CrossRefPubMed

24.

Ando, M., Kawazu, M., Ueno, T., Fukumura, K., Yamato, A., Soda, M., et al. (2013). Cancer-associated missense mutations of caspase-8 activate nuclear factor-kappaB signaling. Cancer Sci, 104(8), 1002–1008. https://doi.org/10.1111/cas.12191.CrossRefPubMedPubMedCentral

25.

Stupack, D. G. (2013). Caspase-8 as a therapeutic target in cancer. Cancer Lett, 332(2), 133–140. https://doi.org/10.1016/j.canlet.2010.07.022.CrossRefPubMed

26.

Braga Lda, C., Silva, L. M., Ramos, A. P., Piedade, J. B., Vidigal, P. V., Traiman, P., et al. (2014). Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer. Biomed Pharmacother, 68(1), 87–91. https://doi.org/10.1016/j.biopha.2013.12.004.CrossRefPubMed

27.

Kim, M., Hernandez, L., & Annunziata, C. M. (2016). Caspase 8 expression may determine the survival of women with ovarian cancer. Cell Death & Disease, 7, e2045. https://doi.org/10.1038/cddis.2015.398.CrossRef

28.

Yan, X. Y., Zhong, X. R., Yu, S. H., Zhang, L. C., Liu, Y. N., Zhang, Y., et al. (2019). p62 aggregates mediated caspase 8 activation is responsible for progression of ovarian cancer. J Cell Mol Med, 23(6), 4030–4042. https://doi.org/10.1111/jcmm.14288.CrossRefPubMedPubMedCentral

29.

Aaboud, M., Aad, G., Abbott, B., Abdinov, O., Abeloos, B., Abhayasinghe, D. K., et al. (2019). Observation of electroweak production of a same-sign w boson pair in association with two jets in pp collisions at sqrt[s] = 13 TeV with the ATLAS Detector. Phys Rev Lett, 123(16), 161801. https://doi.org/10.1103/PhysRevLett.123.161801.CrossRefPubMed

30.

Braga, L. D. C., Goncales, N. G., Furtado, R. S., Andrade, W. P., Silva, L. M., & Silva Filho, A. L. D. (2020). Apoptosis-related gene expression can predict the response of ovarian cancer cell lines to treatment with recombinant human TRAIL alone or combined with cisplatin. Clinics (Sao Paulo), 75, e1492. https://doi.org/10.6061/clinics/2020/e1492.CrossRef

31.

Hensley, P., Mishra, M., & Kyprianou, N. (2013). Targeting caspases in cancer therapeutics. Biol Chem, 394(7), 831–843. https://doi.org/10.1515/hsz-2013-0128.CrossRefPubMedPubMedCentral

32.

Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., et al. (2017). Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A, 114(51), E10981–E10990. https://doi.org/10.1073/pnas.1712514114.CrossRefPubMedPubMedCentral

33.

Koschny, R., Brost, S., Hinz, U., Sykora, J., Batke, E. M., Singer, S., et al. (2013). Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer, 13, 532. https://doi.org/10.1186/1471-2407-13-532.CrossRefPubMedPubMedCentral

34.

Manzo-Merino, J., Massimi, P., Lizano, M., & Banks, L. (2014). The human papillomavirus (HPV) E6 oncoproteins promotes nuclear localization of active caspase 8. Virology, 450-451, 146–152. https://doi.org/10.1016/j.virol.2013.12.013.CrossRefPubMed

35.

Muller, I., Strozyk, E., Schindler, S., Beissert, S., Oo, H. Z., Sauter, T., et al. (2020). Cancer cells employ nuclear caspase-8 to overcome the p53-dependent G2/M Checkpoint through Cleavage of USP28. Mol Cell, 77(5), 970–984 e977. https://doi.org/10.1016/j.molcel.2019.12.023.CrossRefPubMedPubMedCentral

36.

Coleman, R. E., Gregory, W., Marshall, H., Wilson, C., & Holen, I. (2013). The metastatic microenvironment of breast cancer: clinical implications. Breast, 22(Suppl 2), S50–S56. https://doi.org/10.1016/j.breast.2013.07.010.CrossRefPubMed

37.

Ghoneum, A., Afify, H., Salih, Z., Kelly, M., & Said, N. (2018). Role of tumor microenvironment in the pathobiology of ovarian cancer: insights and therapeutic opportunities. [Review]. Cancer Med, 7(10), 5047–5056. https://doi.org/10.1002/cam4.1741.CrossRefPubMedPubMedCentral

38.

Soysal, S. D., Tzankov, A., & Muenst, S. E. (2015). Role of the tumor microenvironment in breast cancer. Pathobiology, 82(3-4), 142–152. https://doi.org/10.1159/000430499.CrossRefPubMed

39.

Hu, M., & Polyak, K. (2008). Microenvironmental regulation of cancer development. Current Opinion in Genetics & Development, 18(1), 27–34. https://doi.org/10.1016/j.gde.2007.12.006.CrossRef

40.

Wang, X. P., Zhao, X. B., Wang, K., Wu, L., & Duan, T. (2013). Interaction of monocytes/macrophages with ovarian cancer cells promotes angiogenesis in vitro. Cancer Science, 104(4), 516–523. https://doi.org/10.1111/cas.12110.CrossRefPubMedPubMedCentral

41.

Weigert, A., Tzieply, N., von Knethen, A., Johann, A. M., Schmidt, H., Geisslinger, G., et al. (2007). Tumor cell apoptosis polarizes macrophages - role of sphingosine-1-phosphate. Molecular Biology of the Cell, 18(10), 3810–3819. https://doi.org/10.1091/mbc.E06-12-1096.CrossRefPubMedPubMedCentral

42.

Paez, D., Labonte, M. J., Bohanes, P., Zhang, W., Benhanim, L., Ning, Y., et al. (2012). Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res, 18(3), 645–653. https://doi.org/10.1158/1078-0432.CCR-11-2186.CrossRefPubMed

43.

Ahmed, N., & Stenvers, K. L. (2013). Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol, 3, 256. https://doi.org/10.3389/fonc.2013.00256.CrossRefPubMedPubMedCentral

44.

Lengyel, E. (2010). Ovarian cancer development and metastasis. Am J Pathol, 177(3), 1053–1064. https://doi.org/10.2353/ajpath.2010.100105.CrossRefPubMedPubMedCentral

45.

Jiang, Y., Wang, C., & Zhou, S. (2020). Targeting tumor microenvironment in ovarian cancer: premise and promise. Biochim Biophys Acta Rev Cancer, 188361. https://doi.org/10.1016/j.bbcan.2020.188361.

46.

Gupta, V., Yull, F., & Khabele, D. (2018). Bipolar tumor-associated macrophages in ovarian cancer as targets for therapy. Cancers (Basel), 10(10). https://doi.org/10.3390/cancers10100366.

47.

Prenen, H., & Mazzone, M. (2019). Tumor-associated macrophages: a short compendium. Cellular and Molecular Life Sciences, 76(8), 1447–1458. https://doi.org/10.1007/s00018-018-2997-3.CrossRefPubMed

48.

Mancino, A., & Lawrence, T. (2010). Nuclear Factor-kappa B and Tumor-Associated Macrophages. Clinical Cancer Research, 16(3), 784–789. https://doi.org/10.1158/1078-0432.Ccr-09-1015.CrossRefPubMedPubMedCentral

49.

Sica, A., Saccani, A., Bottazzi, B., Polentarutti, N., Vecchi, A., van Damme, J., et al. (2000). Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol, 164(2), 762–767. https://doi.org/10.4049/jimmunol.164.2.762.CrossRefPubMed

50.

Wilson, A. J., Saskowski, J., Barham, W., Khabele, D., & Yull, F. (2015). Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer. Mol Cancer, 14, 192. https://doi.org/10.1186/s12943-015-0463-5.CrossRefPubMedPubMedCentral

51.

Kang, T. B., Ben-Moshe, T., Varfolomeev, E. E., Pewzner-Jung, Y., Yogev, N., Jurewicz, A., et al. (2004). Caspase-8 serves both apoptotic and nonapoptotic roles. J Immunol, 173(5), 2976–2984. https://doi.org/10.4049/jimmunol.173.5.2976.CrossRefPubMed

52.

Rebe, C., Cathelin, S., Launay, S., Filomenko, R., Prevotat, L., L'Ollivier, C., et al. (2007). Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation. Blood, 109(4), 1442–1450. https://doi.org/10.1182/blood-2006-03-011585.CrossRefPubMed

53.

Guery, L., Benikhlef, N., Gautier, T., Paul, C., Jego, G., Dufour, E., et al. (2011). Fine-tuning nucleophosmin in macrophage differentiation and activation. Blood, 118(17), 4694–4704. https://doi.org/10.1182/blood-2011-03-341255.CrossRefPubMedPubMedCentral

54.

Roca, H., Varsos, Z. S., Sud, S., Craig, M. J., Ying, C., & Pienta, K. J. (2009). CCL2 and interleukin-6 promote survival of human CD11b + peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem, 284(49), 34342–34354. https://doi.org/10.1074/jbc.M109.042671.CrossRefPubMedPubMedCentral

55.

Chomarat, P., Banchereau, J., Davoust, J., & Palucka, A. K. (2000). IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nature Immunology, 1(6), 510–514. https://doi.org/10.1038/82763.CrossRefPubMed

56.

Cuda, C. M., Misharin, A. V., Khare, S., Saber, R., Tsai, F., Archer, A. M., et al. (2015). Conditional deletion of caspase-8 in macrophages alters macrophage activation in a RIPK-dependent manner. Arthritis Res Ther, 17, 291. https://doi.org/10.1186/s13075-015-0794-z.CrossRefPubMedPubMedCentral

57.

Belgiovine, C., Bello, E., Liguori, M., Craparotta, I., Mannarino, L., Paracchini, L., et al. (2017). Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer, 117(5), 628–638. https://doi.org/10.1038/bjc.2017.205.CrossRefPubMedPubMedCentral

58.

D'Incalci, M., & Galmarini, C. M. (2010). A Review of Trabectedin (ET-743): A unique mechanism of action. Molecular Cancer Therapeutics, 9(8), 2157–2163. https://doi.org/10.1158/1535-7163.Mct-10-0263.CrossRefPubMed

59.

Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., et al. (2013). Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell, 23(2), 249–262. https://doi.org/10.1016/j.ccr.2013.01.008.CrossRefPubMed

60.

Germano, G., Frapolli, R., Simone, M., Tavecchio, M., Erba, E., Pesce, S., et al. (2010). Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res, 70(6), 2235–2244. https://doi.org/10.1158/0008-5472.CAN-09-2335.CrossRefPubMed

61.

Larsen, A. K., Galmarini, C. M., & D'Incalci, M. (2016). Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol, 77(4), 663–671. https://doi.org/10.1007/s00280-015-2918-1.CrossRefPubMed

62.

Hartwig, T., Montinaro, A., von Karstedt, S., Sevko, A., Surinova, S., Chakravarthy, A., et al. (2017). The TRAIL Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. Mol Cell, 65(4), 730–742 e735. https://doi.org/10.1016/j.molcel.2017.01.021.CrossRefPubMedPubMedCentral

63.

Antonopoulos, C., & Dubyak, G. R. (2014). Chemotherapy engages multiple pathways leading to IL-1beta production by myeloid leukocytes. Oncoimmunology, 3(1), e27499. https://doi.org/10.4161/onci.27499.CrossRefPubMedPubMedCentral

64.

Gaillard, S., A, O., Ray-Coquard, I. L., Vergote, I. B., Scambia, G., Colombo, N., Ghamande, S. A., Soto-Matos, A., Fernandez, C. M., Kahatt, C., Gomez, J., Nieto, A., Torres, N., Pardo-Burdalo, B., Papai, Z., Kristeleit, R., O'Malley, D. M., Benjamin, I., Pautier, P., & Lorusso, D. (2018). Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: results of CORAIL trial. Annals of Oncology, suppl_8(2), viii332–viii358. https://doi.org/10.1093/annonc/mdy285.CrossRef

65.

Salmena, L., Lemmers, B., Hakem, A., Matysiak-Zablocki, E., Murakami, K., Au, P. Y. B., et al. (2003). Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes & Development, 17(7), 883–895. https://doi.org/10.1101/gad.1063703.CrossRef

66.

Lemmers, B., Salmena, L., Bidere, N., Su, H., Matysiak-Zablocki, E., Murakami, K., et al. (2007). Essential role for caspase-8 in toll-like receptors and NF kappa B signaling. Journal of Biological Chemistry, 282(10), 7416–7423. https://doi.org/10.1074/jbc.M606721200.CrossRefPubMed

67.

Drakes, M. L., & Stiff, P. J. (2018). Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers (Basel), 10(9). https://doi.org/10.3390/cancers10090302.

68.

Santoiemma, P. P., & Powell Jr., D. J. (2015). Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther, 16(6), 807–820. https://doi.org/10.1080/15384047.2015.1040960.CrossRefPubMedPubMedCentral

69.

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899. https://doi.org/10.1016/j.cell.2010.01.025.CrossRefPubMedPubMedCentral

70.

Savage, P. A., Malchow, S., & Leventhal, D. S. (2013). Basic principles of tumor-associated regulatory T cell biology. Trends Immunol, 34(1), 33–40. https://doi.org/10.1016/j.it.2012.08.005.CrossRefPubMed

71.

deLeeuw, R. J., Kost, S. E., Kakal, J. A., & Nelson, B. H. (2012). The prognostic value of FoxP3+ tumor-Infiltrating Lymphocytes in cancer: a critical review of the literature. Clinical Cancer Research, 18(11), 3022–3029. https://doi.org/10.1158/1078-0432.Ccr-11-3216.CrossRefPubMed

72.

Yang, C., Lee, H., Jove, V., Deng, J., Zhang, W., Liu, X., et al. (2013). Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS One, 8(1), e54029. https://doi.org/10.1371/journal.pone.0054029.CrossRefPubMedPubMedCentral

73.

Milne, K., Kobel, M., Kalloger, S. E., Barnes, R. O., Gao, D., Gilks, C. B., et al. (2009). Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One, 4(7), e6412. https://doi.org/10.1371/journal.pone.0006412.CrossRefPubMedPubMedCentral

74.

Meza-Perez, S., & Randall, T. D. (2017). Immunological functions of the omentum. Trends Immunol, 38(7), 526–536. https://doi.org/10.1016/j.it.2017.03.002.CrossRefPubMedPubMedCentral

75.

Luk, C. T. (2017). Caspase 8 plays a pivotal role in adipose tissue inflammatory signalling and glucose homeostasis. Canadian Journal of Diabetes, 40(5), 59.CrossRef

76.

Luk, C. T., Shi, S. Y., Cai, E. P., Sivasubramaniyam, T., Krishnamurthy, M., Brunt, J. J., et al. (2017). FAK signalling controls insulin sensitivity through regulation of adipocyte survival. Nat Commun, 8, 14360. https://doi.org/10.1038/ncomms14360.CrossRefPubMedPubMedCentral

77.

Gautheron, J., Vucur, M., Schneider, A. T., Severi, I., Roderburg, C., Roy, S., et al. (2016). The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance. Nature Communications, 7, ARTN 11869. https://doi.org/10.1038/ncomms11869.CrossRef

78.

Zoller, V., Funcke, J. B., Roos, J., Dahlhaus, M., El Hay, M. A., Holzmann, K., et al. (2017). Trail (TNF-related apoptosis-inducing ligand) induces an inflammatory response in human adipocytes. Scientific Reports, 7, ARTN 5691. https://doi.org/10.1038/s41598-017-05932-7.CrossRef

79.

Keuper, M., Asterholm, I. W., Scherer, P. E., Westhoff, M. A., Moller, P., Debatin, K. M., et al. (2013). TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma. Cell Death & Disease, 4, ARTN e474. https://doi.org/10.1038/cddis.2012.212.CrossRef

80.

Zoller, V., Funcke, J. B., Keuper, M., Abd El Hay, M., Debatin, K. M., Wabitsch, M., et al. (2016). TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors. Cell Death & Disease, 7, ARTN e2412. https://doi.org/10.1038/cddis.2016.286.CrossRef

81.

Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., et al. (2011). Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res, 71(7), 2455–2465. https://doi.org/10.1158/0008-5472.CAN-10-3323.CrossRefPubMed

82.

Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., et al. (2011). Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med, 17(11), 1498–1503. https://doi.org/10.1038/nm.2492.CrossRefPubMedPubMedCentral

83.

Tan, J. X., Buache, E., Chenard, M. P., Dali-Youcef, N., & Rio, M. C. (2011). Adipocyte is a non-trivial, dynamic partner of breast cancer cells. International Journal of Developmental Biology, 55(7-9), 851–859. https://doi.org/10.1387/ijdb.113365jt.CrossRefPubMed

84.

Correa, L. H., Correa, R., Farinasso, C. M., Dourado, L. P. D., & Magalhaes, K. G. (2017). Adipocytes and macrophages interplay in the orchestration of tumor microenvironment: new implications in cancer progression. Frontiers in Immunology, 8, ARTN 1129. https://doi.org/10.3389/fimmu.2017.01129.CrossRef

85.

Spencer, M., Yao-Borengasser, A., Unal, R., Rasouli, N., Gurley, C. M., Zhu, B. B., et al. (2010). Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. American Journal of Physiology-Endocrinology and Metabolism, 299(6), E1016–E1027. https://doi.org/10.1152/ajpendo.00329.2010.CrossRefPubMedPubMedCentral

86.

van der Steen, S. C., Raave, R., Langerak, S., van Houdt, L., van Duijnhoven, S. M., van Lith, S. A., et al. (2017). Targeting the extracellular matrix of ovarian cancer using functionalized, drug loaded lyophilisomes. Eur J Pharm Biopharm, 113, 229–239. https://doi.org/10.1016/j.ejpb.2016.12.010.CrossRefPubMed

87.

Teitz, T., Inoue, M., Valentine, M. B., Zhu, K. J., Rehg, J. E., Zhao, W., et al. (2013). Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Research, 73(13), 4086–4097. https://doi.org/10.1158/0008-5472.Can-12-2681.CrossRefPubMedPubMedCentral

88.

Lee, P., Lee, D. J., Chan, C., Chen, S. W., Ch'en, I., & Jamora, C. (2009). Dynamic expression of epidermal caspase 8 simulates a wound healing response. Nature, 458(7237), 519–U517. https://doi.org/10.1038/nature07687.CrossRefPubMed

89.

Stupack, D. G., Teitz, T., Potter, M. D., Mikolon, D., Houghton, P. J., Kidd, V. J., et al. (2006). Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature, 439(7072), 95–99. https://doi.org/10.1038/nature04323.CrossRefPubMed

90.

Teitz, T., Stupack, D. G., & Lahti, J. M. (2006). Halting neuroblastoma metastasis by controlling integrin-mediated death. Cell Cycle, 5(7), 681–685. https://doi.org/10.4161/cc.5.7.2615.CrossRefPubMed

91.

Fianco, G., Contadini, C., Ferri, A., Cirotti, C., Stagni, V., & Barila, D. (2018). Caspase-8: a novel target to overcome resistance to chemotherapy in glioblastoma. International Journal of Molecular Sciences, 19(12), ARTN 3798. https://doi.org/10.3390/ijms19123798.CrossRef

92.

Fianco, G., Mongiardi, M. P., Levi, A., De Luca, T., Desideri, M., Trisciuoglio, D., et al. (2017). Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma. Elife, 6, ARTN e22593. https://doi.org/10.7554/eLife.22593.CrossRef

93.

Lamkanfi, M., Declercq, W., Vanden Berghe, T., & Vandenabeele, P. (2006). Caspases leave the beaten track: caspase-mediated activation of NF-kappa B. Journal of Cell Biology, 173(2), 165–171. https://doi.org/10.1083/jcb.200509092.CrossRefPubMedPubMedCentral

94.

Su, H., Bidere, N., Zheng, L. X., Cubre, A., Sakai, K., Dale, J., et al. (2005). Requirement for caspase-8 in NF-kappa B activation by antigen receptor. Science, 307(5714), 1465–1468. https://doi.org/10.1126/science.1104765.CrossRefPubMed

95.

Henry, C. M., & Martin, S. J. (2017). Caspase-8 Acts in a Non-enzymatic role as a scaffold for assembly of a pro-inflammatory "FADDosome" complex upon TRAIL stimulation. Mol Cell, 65(4), 715–729 e715. https://doi.org/10.1016/j.molcel.2017.01.022.CrossRefPubMed

96.

Lim, B., Allen, J. E., Prabhu, V. V., Talekar, M. K., Finnberg, N. K., & El-Deiry, W. S. (2015). Targeting TRAIL in the treatment of cancer: new developments. Expert Opinion on Therapeutic Targets, 19(9), 1171–1185. https://doi.org/10.1517/14728222.2015.1049838.CrossRefPubMed

97.

Moisan, F., Francisco, E. B., Brozovic, A., Duran, G. E., Wang, Y. C., Chaturvedi, S., et al. (2014). Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol, 8(7), 1231–1239. https://doi.org/10.1016/j.molonc.2014.03.016.CrossRefPubMedPubMedCentral

98.

Wang, J., Zhuang, Z. G., Xu, S. F., He, Q., Shao, Y. G., Ji, M., et al. (2015). Expression of CCL2 is significantly different in five breast cancer genotypes and predicts patient outcome. International Journal of Clinical and Experimental Medicine, 8(9), 15684–15691.PubMedPubMedCentral

99.

Zhang, J., Patel, L., & Pienta, K. J. (2010). CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine & Growth Factor Reviews, 21(1), 41–48. https://doi.org/10.1016/j.cytogfr.2009.11.009.CrossRef

100.

Apte, R. N., Dotan, S., Elkabets, M., White, M. R., Reich, E., Carmi, Y., et al. (2006). The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer and Metastasis Reviews, 25(3), 387–408. https://doi.org/10.1007/s10555-006-9004-4.CrossRefPubMed

101.

Safa, A. R. (2013). Roles of c-FLIP in apoptosis, necroptosis, and autophagy. J Carcinog Mutagen, Suppl, 6. https://doi.org/10.4172/2157-2518.S6-003.

102.

Antonopoulos, C., El Sanadi, C., Kaiser, W. J., Mocarski, E. S., & Dubyak, G. R. (2013). Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1beta via caspase-8 in dendritic cells. J Immunol, 191(9), 4789–4803. https://doi.org/10.4049/jimmunol.1300645.CrossRefPubMed

103.

Moen, S. H., Westhrin, M., Zahoor, M., Norgaard, N. N., Hella, H., Stordal, B., et al. (2016). Caspase-8 regulates the expression of pro- and anti-inflammatory cytokines in human bone marrow-derived mesenchymal stromal cells. Immun Inflamm Dis, 4(3), 327–337. https://doi.org/10.1002/iid3.117.CrossRefPubMedPubMedCentral

Title: The role of caspase-8 in the tumor microenvironment of ovarian cancer
Authors: Izabela Kostova
Ranadip Mandal
Sven Becker
Klaus Strebhardt
Publication date: 01-03-2021
Publisher: Springer US
Keywords: Ovarian Cancer
Ovarian Cancer
Cytokines
Published in: Cancer and Metastasis Reviews / Issue 1/2021
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-020-09935-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Potential mechanisms of tumor progression associated with postoperative infectious complications

Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies

Beyond tradition and convention: benefits of non-traditional model organisms in cancer research

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

Current methods in translational cancer research

Potential late effects of SARS-CoV-2 (COVID-19) infection: parallels to cancer late effects

Keynote webinar | Spotlight on antibody–drug conjugates in cancer